US Patent Issued to Cardiff Oncology on April 21 for "PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer" (California Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,616, issued on April 21, was assigned to Cardiff Oncology Inc. (San Diego).

"PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer" was invented by Maya Ridinger (San Diego) and Mark Erlander (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer...